CMC Biologics
Contract development and manufacturing for biopharmaceutical products
About CMC Biologics
CMC Biologics was a contract development and manufacturing organization (CDMO) founded in Copenhagen, Denmark, in 2001. The company specialized in providing integrated services for the development and manufacturing of protein-based therapeutics, such as monoclonal antibodies and other therapeutic proteins, for clients in the pharmaceutical and biotech industries.
The company's services spanned the entire drug development lifecycle, from cell line and process development to cGMP manufacturing for preclinical, clinical, and commercial use. It operated facilities in Copenhagen, Denmark, and in the U.S. in Seattle, Washington, and Berkeley, California. In 2015, Gustavo Mahler, a biopharmaceutical industry veteran with 20 years of experience, including 15 years at Bayer, became the CEO. Under his leadership, the company experienced significant growth.
In December 2016, a definitive agreement was announced for AGC Asahi Glass (AGC), a Japanese manufacturer of glass and chemicals, to acquire all shares of CMC Biologics for approximately $511 million. This acquisition was part of AGC's strategy to expand its life sciences business. Following the acquisition, in January 2018, CMC Biologics was merged with AGC Bioscience and Biomeva GmbH to form a new global CDMO named AGC Biologics. The new entity, headquartered in Bothell, Washington, combines the expertise and facilities of the merged companies to offer a broader range of services in both microbial and mammalian-based manufacturing across a global network.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2016 | $462M | $462M | AGC | ↗ |
| GROWTH EQUITY VCOther financing | Feb 2008 | $165M | — | Monitor Clipper Funds · European Equity Partners | — |
Growth signals
Latest recorded traffic for CMC Biologics is 240 monthly website visits, down 50% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CMC Biologics in the Copenhagen ecosystem
The CMC Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Innoven Partners
Series B and later2 investors entered at this stage
Monitor Clipper Funds- EPEuropean Equity Partners
Other known investors1 additional known investor
AGC
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CMC Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CMC Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









